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Hematopoietic cell transplantation is a common procedure
for the treatment of malignancies and some non-malignant
hematologic disorders. In addition to other transplant-related
organ toxicities, acute renal failure is a common complication
following transplantation. This review discusses the
incidence, timing, etiologies, risk factors, and prognosis of
renal failure associated with three commonly used
transplantation procedures – myeloablative autologous,
myeloablative allogeneic, and non-myeloablative allogeneic
transplantation. It is important to note that the epidemiology
and prognosis of renal failure are distinct with these three
transplantation procedures. However, the common theme is
that mortality increases with worsening renal failure with all
three procedures. Moreover, mortality is 480% for patients
with renal failure requiring dialysis. It also appears that
surviving patients have an increased risk of chronic kidney
disease after renal failure. The reduction of acute renal failure
will have several advantages, including reducing mortality
and the burden of chronic kidney disease following
transplantation.
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Hematopoietic cell transplantation is the only cure for
advanced non-malignant and malignant hematologic dis-
orders and some non-hematologic malignancies. Renal injury
is a common complication and portends worse morbidity
and mortality in these patients. Currently, three types of trans-
plantations exist: myeloablative autologous (commonly known
as autologous), myeloablative allogeneic (conventional
allogeneic), and non-myeloablative allogeneic (mini-allo).
The incidence, etiology, severity, and prognosis of acute
renal failure vary among the three types of transplantations.
Previous publications and reviews have not focused on the
differences in renal failure between these three procedures.1,2
This review will discuss the unique characteristics of renal
injury and the clinical outcomes in autologous, myeloabla-
tive, and non-myeloablative transplantation.
HEMATOPOIETIC CELL TRANSPLANTATION – BACKGROUND
Prevalence of transplantation
Primarily an uncommon and unsuccessful procedure in the
1960s and 1970s, hematopoietic cell transplantation has
become an effective and popular treatment since the 1980s.
The annual use of all hematopoietic cell transplantations
increased to a peak of nearly 55 000 worldwide in the late
1990s, and has now plateaued (www.ibmtr.org). Over the
past 5 years, approximately 30 000 autologous, 15 000
myeloablative allogeneic, and 1350 non-myeloablative
allogeneic transplantations are being performed annually.
Some common indications for transplantation are listed in
Table 1.
Source of donor cells
There are three possible sources of hematopoietic cells: the
affected patient (autologous), a sibling or unrelated donor
(allogeneic), or umbilical cord blood (allogeneic). The source
of hematopoietic stem cells has expanded over time. Initially,
the bone marrow was the source of cells for most
transplantations, hence the older term bone marrow
transplant. However, recently, usage of recombinant human
granulocyte colony-stimulating factor, which increases
the amount of stem cells that enter the peripheral blood
by approximately 1000-fold, has allowed cytopheresis
techniques to become the dominant mode of stem cell
harvesting.
m i n i r e v i e w http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 12 September 2005; revised 20 September 2005; accepted 3
October 2005; published online 4 January 2006
Correspondence: CR Parikh, Section of Nephrology, Yale University and
VAMC, 950 Campbell Avenue, Bdlg 35A, Room 219, West Haven, Connecticut
06516, USA. E-mail: Chirag.Parikh@yale.edu
430 Kidney International (2006) 69, 430–435
Myeloablative versus non-myeloablative
Transplantations can also be of the myeloablative or non-
myeloablative type (Table 2). This differentiation is based on
the ‘conditioning regimen’. Myeloablation generally involves
high-dose chemotherapy with or without total body irradia-
tion. It serves to eradicate the underlying disease and to
provide adequate immunosuppression to prevent rejection of
the transplanted graft. Because of extensive toxicities
(mucositis, nausea, vomiting, diarrhea, rash, neuropathies,
pulmonary fibrosis, and hepatic veno-occlusive disease)
related to myeloablative regimens, myeloablative transplanta-
tion has often been limited to younger patients (ageo50
years) without significant comorbidities. Unfortunately,
several diseases that may benefit from transplantation (acute
and chronic leukemias, lymphomas, myelodysplastic syn-
dromes, multiple myeloma) occur in patients over age 60
years. Clinicians have, therefore, developed a less toxic
regimen, termed non-myeloablative or ‘mini-allo’ transplan-
tation, which involves a lower dose conditioning regimen
(low-dose radiation and/or lower dose of chemotherapy).
The goals for non-myeloablative regimens are not for
eradication of the marrow or malignant cells, but rather to
provide immunosuppression in order to allow engraftment
of the transplanted stem cells. Furthermore, a graft versus
tumor effect mediated by the donor cells is the primary
desired curative effect in non-myeloablative transplantation.
INCIDENCE AND TIMING OF RENAL FAILURE
IN TRANSPLANTATION
Myeloablative allogeneic
Renal failure, for the purposes of this review, will be defined
as an acute fall in glomerular filtration rateZ50% or at least
a doubling of serum creatinine. Following the seminal
publication by Zager et al., renal failure has been recognized
as a common and debilitating complication of transplanta-
tion.1,2 This initial report, representing a cohort of 272
patients with primarily hematologic malignancies who
underwent transplantation (89% allogeneic, 11% auto-
logous) at the Fred Hutchison Cancer Research Center in
Seattle, WA, revealed that 53% of patients developed renal
failure.1 Mean onset of renal failure occurred at 14 days.
Table 2 | Distinguishing features of the three types of hematopoietic cell transplantations
Myeloablative autologous Myeloablative allogeneic Non-myeloablative allogeneic
Number in US (annual) 15 000 7500 1350
Age Mostly younger Younger Older
% recipients age 460 20% o10% 40%
Conditioning regimen
Radiation +/ 12 Gy 2 Gy
Cytotoxic therapy High dose High dose Low dose
Donor cells PB (96%) PB (60%) PB (96%)
BM (4%) BM (38%) Other (4%)
CB (2%)
GVT effect None Mild/moderate Main effect
VOD (incidence) 4–7% 14–54% Extremely rare
TM (incidence) 0–27% 0–76% Extremely rare
Pancytopenia Shorter (B2 weeks) Longer (B3 weeks) Shorter (B2 weeks)
Acute GVHD (II–IV)
Timing
Incidence N/A Early (weeks) Later
Prophylaxis N/A 38–91% 47–77%
N/A MTX/CsA7Pred CsA or Tac7Pred
Chronic extensive GVHD (incidence) N/A 58–71% 46–73%
Overall mortality
100 days B5–20% B20–25% B5–15%
1 year B25–30% B40–45% B35–40%
Gy, Gray; PB, peripheral blood; BM, bone marrow; CB, cord blood; GVT, graft versus tumor; VOD, veno-occlusive disease; TM, thrombotic microangiopathy; GVHD, graft versus
host disease; MTX, methotrexate; CsA, cyclosporine; Tac, tacrolimus; N/A, not applicable.
Data from references 1, 3–11 and www.ibmtr.org.
Table 1 | Indications for HCT in North America (ranked by
absolute number performed annually)
Autologous Allogeneic
Multiple myeloma Acute myelogenous leukemia
Non-Hodgkin’s lymphoma Acute lymphocytic leukemia
Hodgkin’s lymphoma Myelodysplastic syndrome
Other cancersa Non-Hodgkin’s lymphoma
Neuroblastoma Chronic myelogenous leukemia
Breast cancer Non-malignant diseaseb
Chronic lymphocytic leukemia
aOther cancers include acute myelogenous leukemia, acute lymphocytic leukemia,
chronic myelogenous leukemia, chronic lymphocytic leukemia, germ cell tumors,
ovarian cancer, small cell lung cancer, and central nervous system tumors.
bNon-malignant disease includes aplastic anemia, Fanconi anemia, thalassemia,
sickle cell disease, congenital immune deficiencies, and inherited metabolic
diseases.
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Following this publication, several additional studies con-
firmed a similar timing and extremely high incidence of renal
failure following myeloablative allogeneic transplantation
(Figure 1).3–6
Non-myeloablative allogeneic
The differences between the incidence, features, and severity
of renal failure between the three types of transplantation
procedures have only recently been recognized.6,7 As
mentioned above, elderly persons and those with comorbid
conditions may be eligible for non-myeloablative transplan-
tation. The non-myeloablative procedure usually has fewer
complications than myeloablative transplantation. For ex-
ample, there is a decreased incidence of cytomegalovirus
infection, pulmonary toxicity, and hyperbilirubinemia, and
platelet and red blood cell transfusion requirements are
markedly decreased. Few reports, until the past 2 years, have
focused on renal injury in the setting of non-myeloablative
transplantation.
We reported on two cohorts: a cohort of 253 patients
undergoing non-myeloablative transplantation at four cen-
ters in the US, and a cohort of 129 patients undergoing non-
myeloablative transplantation at the Fred Hutch Cancer
Research Center, Seattle, WA.6,7 First, it is worth noting that
patients undergoing non-myeloablative transplantation were
older (median age 53 years); greater than 40% were over the
age of 55 years. Second, given their increased age and
comorbidities, those undergoing non-myeloablative trans-
plantation had a much higher incidence of stage 2–5 chronic
kidney disease (CKD) at baseline (59 versus 13% in the
myeloablative group).6
Renal failure occurred in slightly more than 40% of
patients within approximately a 3-month period post-non-
myeloablative transplantation,6,7 which is much lower than
the 76% incidence in myeloablative allogeneic transplanta-
tion (weighted mean of published studies).1,4–6 Controlling
for clinical variables, the risk of developing renal failure
was nearly five-fold less for non-myeloablative trans-
plantation compared with myeloablative regimens.6 This
relationship was also present for dialysis-requiring renal
failure: an incidence of only 4% compared with 17% in
myeloablative transplantation (Figure 1).1,4–7 Additionally,
the onset of renal failure was later, occurring at a
median time of 26–60 days (B14 days in myeloablative
transplantation).1,6,7
Myeloablative autologous
The incidence of renal failure in patients undergoing
autologous transplantation is much lower (22%) than in
myeloablative allogeneic transplantation (Figure 1).8,9 The
reasons for this vast difference are two-fold. In autologous
transplantation, there is no graft versus host disease (GVHD).
GVHD may contribute to nephrotoxicity directly (infra vide)
and indirectly (prophylaxis via calcineurin inhibitors).
Second, because there are no foreign cells, more rapid
engraftment occurs (resulting in less cytopenia, sepsis, and
nephrotoxic antimicrobials).
PATHOGENESIS OF RENAL FAILURE IN TRANSPLANTATION
Several factors unique to the transplantation patient can
contribute to renal injury, resulting in the high frequency and
severity of renal failure in this population. Some of these
factors are discussed in chronological order, beginning at the
time of induction.
Tumor lysis syndrome
Rapid destruction of tumor cells via high-dose radiation and
chemotherapy poses risk for tumor lysis syndrome. Release of
intracellular contents such as uric acid and phosphate may
precipitate in renal tubules, resulting in intratubular
obstruction and renal failure. Fortunately, because many are
in remission at the time of transplantation and because of
appropriate prophylaxis with intravenous fluids, urinary
alkalization, and allopurinol, the incidence of tumor lysis
syndrome in this population is quite low (approximately one
in 400).2
Sepsis
Owing to profound neutropenia as a result of bone marrow
ablation secondary to radiochemotherapy, transplantation
patients are at high risk of both bacterial and fungal sepsis.
The resultant vasodilation and capillary leak following sepsis
contribute to renal hypoperfusion. Cytokine-induced renal
vasoconstriction, cytokine-induced intrarenal inflammation,
and complement-mediated renal injury also contribute to
renal failure in the setting of sepsis.
Agents used to treat bacteremia and sepsis (e.g.,
gentamicin, amphotericin B) may also contribute to
nephrotoxicity in this setting. To underscore the importance
of sepsis in the development of post-transplantation renal
failure, patients who developed dialysis-requiring renal
failure (compared to those who maintained normal renal
function) had a higher incidence of fevers (95 versus 50%)
Autologous Allogeneic
Myeloablative Myeloablative Non-myeloablative
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
35% 18% 4%
Hematopoietic cell transplantation
17%59%25% 49% 39% 4%
ARF ARF ARF
Figure 1 | Incidence of grades of acute renal failure by type of
hematopoietic cell transplantation. ARF: acute renal failure. Grade
1: Less than two-fold rise in serum creatinine with a decrease in
creatinine clearance 425%. Grade 2: Rise in serum creatinine
42-fold but no dialysis required. Grade 3: ARF requiring dialysis.
Incidence (percent) of grades of ARF are weighted means of the
following published studies (where information available): Myelo-
ablative autologous: references 1, 8, 9. Myeloablative allogeneic:
references 1, 4–6. Non-myeloablative allogeneic: references 6, 7.
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and positive blood cultures (63 versus 0%) within 48 h prior
to the onset of renal insufficiency.1
Hepatic veno-occlusive disease
Hepatic veno-occlusive disease is caused by acute radio-
chemotherapy-induced endothelial cell injury of hepatic
venules, which results in venular thrombosis and subsequent
sinusoidal and portal hypertension. Clinically, hepatic veno-
occlusive disease begins as a fluid-retentive state with low
urinary sodium that leads to peripheral edema and weight gain
within the first few days after transplantation, mimicking the
hepatorenal syndrome.10 Hepatomegaly, right upper quadrant
pain, and ascites are also common features.10 Owing to the
hepatocyte injury, transaminases and bilirubin become
elevated. The signs and symptoms of hepatic veno-occlusive
disease precede the development of renal insufficiency.2,10
Risk factors for development of hepatic veno-occlusive
disease include increasing age, pre-existing hepatic disease,
fever, cytomegalovirus seropositivity, and medications (estro-
gen, progestin, amphotericin, methotrexate), including agents
frequently used as part of conditioning regimens (busulfan
and cyclophosphamide).2,10 Overall, hepatic veno-occlusive
disease occurs more commonly in myeloablative allogeneic
compared to autologous transplantation (Table 2).3–6,8,10
The reduced incidence in autologous transplantation may
be due to the absence of methotrexate, since there is no risk
of GVHD, and because of more rapid engraftment. In non-
myeloablative transplantation, hepatic veno-occlusive disease
is non-existent, probably because of the much lower intensity
of the radiochemotherapy.6
Prevention for hepatic veno-occlusive disease can be
moderately successful when heparin infusions and/or urso-
deoxycholic acid are initiated immediately prior to induc-
tion. Recombinant human tissue plasminogen activator and
an agent with pleuripotent properties, defibrotide, have been
employed with mild to moderate success in the treatment of
hepatic veno-occlusive disease (30–40% response rate).
Hematopoietic cell transplantation-associated thrombotic
microangiopathy
Several reports of this specific thrombotic microangiopathy
appear in the literature over the past 25 years. Diagnosis of
this disorder in transplantation patients is difficult, as this
population has several reasons to have anemia, thrombo-
cytopenia, renal dysfunction, fever, and neurological ab-
normalities. Repeated assessment of the peripheral smear to
document microangiopathic anemia (via schistocytes) is
essential. The etiology is more likely due to direct endothelial
injury from calcineurin inhibitors, high-dose chemotherapy,
and total body irradiation, rather than from deficiencies in
von Willenbrand factor-cleaving protease. The incidence of
thrombotic microangiopathy varies greatly in the literature,
ranging from 0 to 74%, because of inconsistencies in
diagnostic criteria.11 In general, the incidence rate is lower
in autologous transplantation and non-existent in non-
myeloablative transplantation. Onset of thrombotic
microangiopathy usually occurs between 20 and 99 days
post-transplantation.11 Risk factors associated with the
development of thrombotic microangiopathy include veno-
occlusive disease, grade II–IV acute GVHD, unrelated donor,
and systemic bacterial, fungal, and viral infections.11
Although many centers utilize plasma exchange for the
treatment of transplantation-associated thrombotic micro-
angiopathy, the response rates to treatment are significantly
lower (45%) than in classical thrombotic microangiopathy
(approximately 75%).
Calcineurin inhibitors
The calcineurin inhibitors (cyclosporine, tacrolimus) are
employed for prophylaxis against GVHD. In myeloablative
allogeneic transplantation patients, they are combined with
methotrexate, and are used with steroids in non-myelo-
ablative transplantation. Both agents are potent renal
vasoconstrictors and induce reductions in renal function
that correlate well with serum concentrations of the drug.2
However, in myeloablative allogeneic transplantation, cyclo-
sporine has not been associated with the development of
renal failure in several studies.1,2,5,12 This is probably due to
frequent adjustments in doses for both high levels and
elevations in serum creatinine. Also, because of several
concurrent toxic insults occurring, it is difficult to statistically
separate the contribution of cyclosporine to renal dysfunc-
tion.
In non-myeloablative transplantation, cyclosporine was
associated with all cases of non-dialysis-requiring renal
failure, and renal function improved with dose reductions.7
Therefore, it is likely that calcineurin inhibitors do a play a
more significant role in renal failure in non-myeloablative
transplantation. Adjustments in dose should be made to
maintain lower levels and when renal dysfunction is present.
Graft versus host disease
Although not classically believed to involve the kidney,
GVHD may affect the kidney through cytokine- and
immune-related injury, including glomerular deposits lead-
ing to nephrotic syndrome, and tubulitis, as recognized by
some authors.13 Support for this theory also arises from mice
that were found to have severe infiltration of their kidneys
with cytotoxic T-cells during GVHD.14 Although usually not
statistically associated with renal failure in studies,1,3,7 further
experimental and human research is needed to establish the
link, if any, between GVHD and renal disease.
RISK FACTORS ASSOCIATED WITH RENAL FAILURE
Myeloablative allogeneic
Renal failure following myeloablative allogeneic transplanta-
tion typically occurs after approximately 2 weeks. At this
time, the patient is most vulnerable to multiple organ
dysfunctions due to toxicities associated with the intense
conditioning regimen, especially infections and hepatic veno-
occlusive disease. Commensurate with these intuitive risks,
the statistically-derived risk factors for development of renal
Kidney International (2006) 69, 430–435 433
CR Parikh and SG Coca: Renal failure in transplantation m i n i r e v i e w
failure in the setting of myeloablative allogeneic transplant-
ation were hepatic veno-occlusive disease,3,5,6,12 pulmonary
toxicity,5,6 older age,3 amphotericin B,12 high-risk malig-
nancy group,6 and increased comorbidity score.6 Factors not
found to be statistically associated with an increased risk of
renal failure in multivariate analyses were sex,1,3 underlying
disease,3,5 conditioning therapy,3,5 total body irradiation,5
hypotension,1,5 aminoglycoside use,5 and related versus
unrelated donors.6
Conflicting results were present among some potential
risk factors. First, hyperbilirubinemia was a risk factor in one
report but not another.1,5 Second, higher serum creatinine at
baseline was associated with a higher risk for renal failure in
one analysis, but a lower risk in another analysis, despite the
fact that both reports and authors originate from the same
institution.1,12
The severity of renal injury following myeloablative
transplantation may be augmented by the destruction of
stem cells available for kidney repair by the radiochemo-
therapy administered with transplantation. Recovery of renal
function may therefore be hampered by the absence of one or
both of the following cell lines: renal adult stem cells that
reside in the renal papilla that normally proliferate during
times of renal injury and are involved in renal repair and/or
mesenchymal stem cells (not administered during infusion of
hematopoietic stem cells) that have renoprotective properties
in experimental animals through currently unknown me-
chanisms.15,16
Non-myeloablative allogeneic
Renal failure, as discussed above, is less severe and occurs
later in non-myeloablative transplantation, probably because
the milder conditioning regimen leads to less severe toxicities.
The major culprit for renal failure in this population is
cyclosporine insult.7 When severe renal failure (dialysis-
requiring) does occur, etiologies are typically multifactorial,
involving cyclosporine plus factors such as severe GVHD,
sepsis, volume depletion, hypotension, hemorrhage, and
antibiotics.7
Myeloablative autologous
Few studies have examined renal toxicity in solely autologous
transplantation. Clinical predictors for renal failure in
multivariate models included liver toxicity, lung toxicity,
and sepsis in one report.8 In a report involving only
autologous transplantation for AL amyloidosis, the clinical
predictors were cardiac involvement, bacteremia, higher
melphelan dose (not a known nephrotoxin), higher urinary
protein excretion, and lower creatinine clearance.9
PROGNOSIS
Mortality
Zager et al.1 first noted the significant differences in mortality
associated with varying degrees of renal failure in transplan-
tation. In patients without renal insufficiency, the mortality
was 17%; in patients with non-dialysis-requiring renal
failure, the mortality was 37%; in patients with dialysis-
requiring renal failure, the mortality was 84%.
Subsequent reports confirmed that the degree of renal
failure is associated with mortality (Figure 2). A meta-
analysis encompassing 1211 patients undergoing myeloabla-
tive allogeneic transplantation found that the relative risk of
death after renal failure was greater than two-fold higher.17
The adjusted odds of 6-month mortality with dialysis-
requiring renal failure was 6.8-fold higher even after
controlling for several demographic, clinical, and transplan-
tation variables.17 Finally, among the studies of myeloablative
allogeneic, myeloablative autologous, or non-myeloablative
allogeneic transplantation, one monumental fact transcends
these categories. The mortality associated with dialysis-
requiring renal failure is similarly devastating among the
three types of transplantation, universally approaching or
exceeding 80% (Figure 2).1,3–5,7,8
A potential reason for the extremely poor outcomes and
survival witnessed with renal failure may be due to
exacerbation of non-renal organ toxicities secondary to
systemic cytokine elaboration and immune-mediated da-
mage initiated by renal injury.18 Indeed, hepatic, pulmonary,
and gastrointestinal toxicities increase as the severity of renal
failure increases in transplantation.5,6
Chronic kidney disease
By 6–12 months after myeloablative allogeneic transplanta-
tion, approximately 20% of patients will develop CKD. The
etiology is likely multifactorial. Renal failure certainly
contributes to long-term impairment in renal function, with
subsequent reductions in mean glomerular filtration rate of
approximately 50% at 6 months.5 In addition, radiation
induces glomerular and interstitial injury in a dose-
dependent fashion that can be abrogated by renal shielding.19
0
10
20
30
40
50
60
70
80
90
M
or
ta
lit
y 
(%
)
Grade 0/1
(<doubling
creatinine)
Grade 2
(>doubling
creatinine)
Grade 3
(dialysis-
requiring)
Acute renal failure
Myeloablative
autologous
Non-myeloablative
Myeloablative
allogeneic
Figure 2 | Acute renal failure-associated mortality by type of
hematopoietic cell transplantation. It is evident that worsening
acute renal failure is associated with an increase in mortality. Patients
who require dialysis have a dismal prognosis. Mortality percentages
are weighted means from the following references: 1, 3, 4, 5, 7, 8.
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Shielding may preserve renal stem cells that reside in the
papilla, thereby enabling renal repair and recovery.15
In non-myeloablative transplantation, the development of
CKD has not been well characterized until recently when a
retrospective cohort of 122 patients undergoing the proce-
dure between 1998 and 2002 was examined. A total of 65%
had development of CKD (defined as a reduction in
glomerular filtration rate of 25% or greater) and 22%
experienced at least a doubling of serum creatinine within 1
year of receiving the non-myeloablative transplantation.20
The greatest risk factor for CKD was acute renal failure (OR
32.8, 95% CI 4.3–250, P¼ 0.0005). Other risk factors
included prior autologous transplantation, chronic extensive
GVHD, and long-term cyclosporine use.
CONCLUSION
Assessment of the etiology, characteristics, incidence, severity,
and prognosis of renal failure following transplantation must
consider the three distinct forms of hematopoietic cell
transplantation. Severe renal failure occurs with all three
varieties, but the frequency increases from myeloablative
autologous, to non-myeloablative allogeneic, to myeloabla-
tive allogeneic. In all three types of transplantation, mortality
is clearly associated with the severity of renal injury, and it is
greater than 80% when dialysis is required.
While the risk factors and etiologies for renal failure in this
population are numerous, efforts must be made to lessen
renal injury in this setting. Reasonable approaches should
involve both direct nephroprotective strategies and refine-
ment of treatment for the extrarenal targets. Currently, tumor
lysis syndrome is generally prevented with fluids, bicarbo-
nate, and allopurinol. Recently, there has been more success
with the treatment of sepsis with advances in antibiotics,
intensive insulin therapy, activated protein C, and physio-
logic doses of corticosteroids. There has been only mixed
success against hepatic veno-occlusive disease with anti-
coagulants/fibrinolytics and defibrotide. Further understand-
ing of the diagnosis and treatment of transplantation-
associated thrombotic microangiopathy is needed, as plasma
exchange is often not curative and potentially hazardous in
this population. Hopefully, novel treatments will become
available for each of these disorders, and reduce their
attendant morbidity and mortality.
Strategies to reduce acute renal failure following trans-
plantation may have a tremendous beneficial impact on this
population. Reduction of acute renal failure will likely reduce
the severity of non-renal organ dysfunction, incidence and
severity of CKD, and mortality.
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